Centers for Disease Control and Prevention

National Center for Immunization and Respiratory Diseases

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation 

use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

ACIP COVID-19 Vaccines Work Group

Dr. Matthew F. Daley, Work Group Chair

Sept 12, 2023
▪ September 11, 2023: 

– FDA updated COVID-19 vaccine emergency use authorizations (EUAs)

• Use of 2023 – 2024 mRNA vaccines for all doses/indications administered to 

individuals ages 6 months – 11 years

– FDA approved supplemental biologics license applications (BLAs)

• Use of 2023 – 2024 mRNA vaccines for all doses/indications administered to 

individuals ages ≥ 12 years

COVID-19 vaccine update:

FDA authorizations and approvals
▪ Updates to COVID-19 epidemiology and vaccine effectiveness, including in pregnant persons and 

infants

▪ Infection-induced and hybrid immunity

▪ Summary and Work Group considerations

– COVID-19 and pregnancy:

• Pregnancy remains a risk factor for severe COVID-19 disease

• COVID-19 vaccination improves outcomes for pregnant people and their infants

– Infection-induced and hybrid immunity:

• Hybrid immunity likely provides better protection than either infection or vaccination alone.

• Protection likely influenced by multiple factors (e.g., prior vaccine doses, infection, time since 

vaccination or infection) 

• Protection wanes over time after both infection and vaccination

June ACIP Meeting Review

June 23, 2023
▪ Manufacturer data to inform monovalent XBB.1.5 containing vaccine update

▪ Modeling of pandemic outcomes in varied scenarios, demonstrating potential impact 

of new variants and varying vaccine/booster coverage

▪ Comprehensive review of COVID-19 vaccine safety

▪ Updated data on COVID-19 epidemiology, vaccine effectiveness, and benefit-risk 

assessment

▪ Epidemiology of post-COVID conditions 

▪ COVID-19 vaccine cost-effectiveness analysis

▪ Evidence to Recommendations Framework

– Work group discussed universal vs. risk-based strategies, reviewed additional data 

on burden (by age group, presence of underlying condition)

ACIP COVID-19 Work Group Meeting Review

July – September 2023
▪ Current landscape of SARS-CoV-2 lineages Dr. Natalie Thornburg 

▪ COVID-19 epidemiology Dr. Fiona Havers

▪ Post-COVID conditions Dr. Sharon Saydah

▪ COVID-19 Vaccine Effectiveness Update Dr. Ruth Link-Gelles

▪ Economic analysis of COVID-19 vaccination Dr. Lisa Prosser

▪ COVID-19 vaccine safety surveillance Dr. Nicola Klein

▪ Break

▪ Moderna 2023 – 2024 COVID-19 vaccine Dr. Fran Priddy

▪ Novavax 2023 – 2024 COVID-19 vaccine Dr. Filip Dubovsky

▪ Pfizer-BioNTech 2023 – 2024 COVID-19 vaccine Dr. Kayvon Modjarrad

Agenda

September 12, 2023
Break

▪ Evidence to Recommendations Dr. Megan Wallace

▪ Overview of COVID-19 vaccine implementation Dr. Georgina Peacock 

▪ Bridge access program Dr. Evelyn Twentyman

▪ Discussion

Break

PUBLIC COMMENT

Break

Vote:

2023 – 2024 COVID-19 vaccines in persons ages 6 months and older

Agenda

September 12, 2023
Work Group members

ACIP members

▪ Matthew Daley (chair)

▪ Beth Bell 

▪ Grace Lee

▪ Keipp Talbot

▪ Oliver Brooks

Ex-officio/government members

▪ FDA: Rachel Zhang, Lucia Lee, Anuja Rastogi

▪ NIH: Chris Roberts, Michael Ison

▪ IHS: Uzo Chukwuma

▪ CMS: Jeff Kelman

▪ BARDA: Christine Oshansky

▪ HHS: Valerie Marshall

▪ CDC: Alan Lam

CDC Leads

▪ Megan Wallace

▪ Joanna Regan

7

Liaisons

▪ AAFP: Jonathan Temte

▪ AAP: Sean O’Leary

▪ ACOG: Denise Jamieson (primary), 

Laura Riley (alternate)

▪ ACP: Jason Goldman

▪ ADS: Emily Kahn

▪ AGS: Ken Schmader

▪ AMA: Sandra Fryhofer

▪ ANA: Ruth Francis (alternate)

▪ APA: Richard Dang

▪ ASTHO: Marcus Plescia

▪ CSTE: Paul Cieslak, Christine Hahn

Liaisons, cont’d

▪ NACCHO: Matt Zahn (primary), 

Jeff Duchin (alternate)

▪ NACI: Matthew Tunis (primary), 

Eva Wong (alternate) 

▪ NFID: Rob Schechter (primary), 

Bill Schaffner (alternate)

▪ NMA: Patricia Whitley-Williams

▪ SHEA: Preeti Mehrotra, 

Marci Drees (alternate)

Consultants

▪ Ed Belongia

▪ Hank Bernstein

▪ Kathy Edwards

▪ Robert Hopkins

▪ Lisa Jackson

▪ Kathy Kinlaw

▪ Dayna Matthew 

▪ Jennifer Nelson

▪ Kathleen Neuzil

▪ Stanley Perlman

▪ Peter Szilagyi
▪ Sarah Meyer

▪ Elisha Hall

▪ Danielle Moulia

▪ Monica Godfrey

▪ Hannah Rosenblum

▪ Katherine Fleming-Dutra

▪ Ruth Link-Gelles

▪ Lauren Roper 

▪ Mary Chamberland

▪ Susan Goldstein

▪ Stephen Hadler

▪ JoEllen Wolicki

▪ Melinda Wharton

▪ Jessica MacNeil

▪ Amanda Cohn

▪ Brooke Aspinwall 

▪ Latifa Boyce 

CDC participants

8

▪ Amadea Britton

▪ Karen Broder 

▪ Carolyn Bridges

▪ Allison Ciesla 

▪ Nicole Dowling

▪ Daniel Drapeau

▪ Tarayn Fairlie

▪ Ashley Fowlkes

▪ Julianne Gee

▪ Samuel Graitcer

▪ Lisa Grohskopf

▪ Katherine Grusich

▪ Aaron Hall 

▪ Demorah Hayes

▪ Rita Helfand

▪ Terri Hyde

▪ Jefferson Jones 

▪ Melisa Shah

▪ Tom Shimabukuro

▪ Jordan Singleton

▪ Laura Steinhardt

▪ John Su

▪ Natalie Thornburg

▪ Evelyn Twentyman 

▪ Dennis Wang

▪ Raigan Wheeler

▪ Ryan Wiegand

▪ Patricia Yu

▪ Yon Yu

▪ Andrew Kroger

▪ Josephine Mak

▪ Lauri Markowitz

▪ Michael McNeil

▪ Michael Melgar

▪ Noelle-Angelique Molinari

▪ Morgan Najdowski

▪ Kristen Nordlund

▪ Sara Oliver 

▪ Ismael Ortega-Sanchez

▪ Manisha Patel

▪ Pragna Patel

▪ Amanda Payne

▪ Georgina Peacock

▪ Jamison Pike 

▪ Derrell Powers

▪ Sierra Scarbrough
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official 

position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation 

use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

Thank you